Show summary Hide summary
SLS stock just surged after beating earnings expectations in a stunning move that could reshape its leukemia treatment prospects. The biotech firm reported better-than-expected losses and advanced a critical drug trial closer to completion. Wall Street is watching intently as this cancer vaccine candidate approaches a pivotal data reveal.
🔥 Quick Facts
- Earnings Beat: SELLAS reported adjusted loss of $0.05 per share, beating analyst estimate of $0.07 loss
- REGAL Trial Status: Phase 3 leukemia study reached 78 of 80 required events, final data imminent
- Cash Position: Company raised $107.1M in cash, strengthening runway through key milestones
- Stock Momentum: SLS has surged over 250% since December 2025 on clinical progress signals
Earnings Beat Ignites Investor Confidence
SELLAS Life Sciences delivered stronger-than-expected financial results today, sending shares higher in afternoon trading. The adjusted loss per share of $0.05 beat analyst expectations of a $0.07 loss, signaling improved operational efficiency. Additionally, the company bolstered its cash reserves to $107.1 million through warrant exercises, providing financial flexibility for upcoming clinical catalysts. Wall Street analysts now see the stock reaching $10.00 within 12 months, nearly double current levels.
The company’s strategic focus on leukemia treatments continues to drive investor enthusiasm. SELLAS is racing toward final data from its Phase 3 REGAL trial, which evaluates its GPS immunotherapy in acute myeloid leukemia patients. With 78 of 80 required events already documented, the company expects to announce pivotal results in the coming months, representing a critical near-term catalyst.
SLS stock surges after earnings beat, leukemia drug trial nears key data
QS stock slides as QuantumScape unveils Eagle Line battery partnerships
Phase 3 Trial Nearing Crucial Milestone
The significance of the REGAL Phase 3 study cannot be overstated. Earlier Phase 2 data showed that patients receiving GPS treatment lived four times longer than those receiving standard care. Additionally, 70% of patients who received more than two doses achieved one-year progression-free survival, a remarkable outcome in AML treatment. With the trial now at 78 of 80 events, final analysis is imminent, which could become a transformative approval catalyst.
Beyond GPS, SELLAS recently initiated an 80-patient Phase 2 trial of its SLS009 candidate in newly diagnosed AML patients. This earlier-line indication represents an enormous market opportunity, as first-line treatments typically see broader adoption than relapsed and refractory settings. The company’s diversified pipeline reduces risk and maximizes upside potential if any single program succeeds.
Financial and Clinical Timeline
| Milestone | Status |
| REGAL Phase 3 Events | 78 of 80 (nearing completion) |
| Q1 2026 Cash Position | $107.1 million |
| SLS009 Phase 2 Start | 80 newly diagnosed AML patients |
| Analyst Price Target | $10.00 (90% upside) |
“We are advancing toward the final analysis of our Phase 3 REGAL trial evaluating GPS in AML patients who have achieved complete remission, with data expected later this year.”
According to SELLAS Life Sciences leadership statement
What Biotech Investors Need To Know
SLS represents a textbook binary event play in oncology biotech. The company’s financial position is solid, with $107 million in cash providing sufficient runway through expected REGAL data readout. Short interest hit 8-year highs ahead of earnings, suggesting a potential short squeeze if REGAL data proves positive. The stock’s 250% rally since December reflects growing confidence in clinical progress.
However, investors must acknowledge the risks inherent to clinical-stage biotech. REGAL results could disappoint, franchise value hinges on GPS approval, and regulatory approval timelines remain unpredictable. The AML market is competitive, and even positive data does not guarantee commercial success. Institutional holders should model both bull and bear case scenarios before committing capital.
Will REGAL Data Trigger the Next Bull Run?
The coming weeks will prove critical for SLS shareholders. Final REGAL Phase 3 data represents the primary near-term catalyst, with positive results potentially unlocking FDA breakthrough designation or accelerated approval pathways. Market consensus suggests $10 per share is achievable if data meets expectations, but downside risk to $3 exists if results disappoint severely.
Beyond REGAL, SLS009 in earlier-line AML could become a multi-billion-dollar asset if Phase 2 data supports advancement. Early patient enrollment suggests demand for new AML options, validating the company’s thesis. For contrarian investors willing to assume clinical risk, SLS offers asymmetric upside ahead of the company’s most important milestone.
Sources
- Investing.com – SELLAS surges on earnings beat and trial update, May 12, 2026
- GlobeNewswire – SELLAS Life Sciences Q1 2026 financial results and corporate update
- Seeking Alpha – SELLAS Life Sciences behind the big surge, detailed clinical analysis
